As it searches for a new CEO, Illumina faces a high-stakes year of challenges
Just two and a half weeks after the abrupt exit of Illumina’s CEO Francis deSouza, the DNA sequencing giant is facing one of the most pivotal periods in its history.
It has promised investors $100 million in cost cuts, is awaiting the final outcome in an antitrust saga stemming from its $7.1 billion acquisition of cancer test developer Grail, and faces competition that wasn’t there a few years ago. This all comes amid its search for a new CEO, who will have to lead the San Diego-based company through those difficulties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.